Fluorouracil Injection
Sponsors
Astrazeneca AB, Catharina Ziekenhuis Stichting, Suzhou Suncadia Biopharmaceuticals Co., Ltd., Rutgers, The State University of New Jersey
Conditions
Advanced Solid TumorAdvanced Solid TumorsBreast NeoplasmsColorectal NeoplasmsGastro-Intestinal Intraepithelial NeoplasiaHead and Neck NeoplasmsLocally Advanced Unresectable Esophageal Squamous Cell CarcinomaLocally advanced rectal cancer
Phase 1
A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With Solid Tumors
RecruitingNCT06703177
Start: 2025-02-18End: 2027-07-01Target: 876Updated: 2025-12-03
A Study of SHR-4375 Injection in Combination With Other Antitumor Therapies in Patients With Solid Tumors
Not yet recruitingNCT07298772
Start: 2025-12-31End: 2028-01-31Target: 198Updated: 2025-12-23
Phase 2
Phase 3
A Phase III, Randomized, Double-Blind, Placebo Controlled, Multi-Center, International Study of Durvalumab Given Concurrently With Definitive Chemoradiation Therapy in Patients With Locally Advanced, Unresectable Esophageal Squamous Cell Carcinoma (KUNLUN).
Active, not recruitingCTIS2023-506413-22-00
Start: 2021-03-31Target: 48Updated: 2026-01-09
Multicentre, open-label, randomized, controlled, parallel arms clinical trial of induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as neoadjuvant treatment for locally recurrent rectal cancer (PelvEx II)
RecruitingCTIS2024-512526-28-00
Start: 2020-10-28Target: 364Updated: 2026-01-19